IDT AUSTRALIA LIMITED (IDT)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
![](/stocklogo/IDT.jpg)
IDT - IDT AUSTRALIA LIMITED
FNArena Sector :
Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -2.59
Index:
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -2.59
LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
---|---|---|---|
$0.13
22 Jul |
0.000 OPEN $0.13 |
0.000 HIGH $0.13 |
337,764 LOW $0.13 |
OTHER COMPANIES IN THE SAME SECTOR | |||
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO . |
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
Last ex-div: 12/04 - (franking Ex-Di
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
EPS Basic | xxx | xxx | xxx | xxx | xxx | -3.4 |
DPS All | xxx | xxx | xxx | xxx | xxx | 0.0 |
Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 6.9 M |
Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 8.1 |
Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | -7.9 M |
Net Profit Margin | xxx | xxx | xxx | xxx | xxx | -122.54 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | -33.24 % |
Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | -33.24 % |
Return on Assets | xxx | xxx | xxx | xxx | xxx | -29.12 % |
Return on Equity | xxx | xxx | xxx | xxx | xxx | -33.24 % |
Return on Total Capital | xxx | xxx | xxx | xxx | xxx | -37.07 % |
Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | -8.4 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Short-Term Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
Long Term Debt | xxx | xxx | xxx | xxx | xxx | 0 M |
Total Debt | xxx | xxx | xxx | xxx | xxx | 1 M |
Goodwill - Gross | xxx | xxx | xxx | xxx | xxx | - |
Cash & Equivalents - Generic | xxx | xxx | xxx | xxx | xxx | 4 M |
Price To Book Value | xxx | xxx | xxx | xxx | xxx | 0.78 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
![](/images/chart-unavailable.png)
Cash & Equivalents - Generic
Price To Book Value
Title | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capex | xxx | xxx | xxx | xxx | xxx | 0.5 M |
Capex % of Sales | xxx | xxx | xxx | xxx | xxx | 7.53 % |
Cost of Goods Sold | xxx | xxx | xxx | xxx | xxx | 10 M |
Selling, General & Admin. Exp & Other | xxx | xxx | xxx | xxx | xxx | 6 M |
Research & Development | xxx | xxx | xxx | xxx | xxx | - |
Investments - Total | xxx | xxx | xxx | xxx | xxx | 0 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
![](/images/chart-unavailable.png)
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
EXTRA COVERAGE
Display All Commentary
No. Of Recommendations
Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.
IDT STOCK CHART
![](/wp-content/uploads/2020/10/img-side-banner-stock-analysis.jpg)
FNArena News on IDT
1 |
February Small Cap Winners & LosersFeb 29 2024 - Small Caps |
2 |
Australian Broker Call *Extra* Edition – Apr 03, 2023Apr 03 2023 - Daily Market Reports |
3 |
Australian Broker Call *Extra* Edition – Nov 22, 2022Nov 22 2022 - Daily Market Reports |
4 |
Australian Broker Call *Extra* Edition – Jul 05, 2022Jul 05 2022 - Daily Market Reports |
5 |
Weekly Ratings, Targets, Forecast ChangesAug 28 2017 - Weekly Reports |
Latest Pharmaceuticals & Biotech/Lifesciences News
1 |
CSL Shares Breaking FreeJul 23 2024 - Technicals |
2 |
Dr Boreham’s Crucible: SDIJul 19 2024 - Small Caps |
3 |
‘Defensive’ Pharmaceutical Wholesalers In FocusJul 18 2024 - Australia |
4 |
Twists And Turns Of Telix And Australian BiotechJul 10 2024 - Small Caps |
5 |
Dr Boreham’s Crucible: Radiopharm TheranosticsJul 03 2024 - Small Caps |
6 |
Dr Boreham’s Crucible: Island TherapeuticsJun 17 2024 - Small Caps |
7 |
Dr Boreham’s Crucible: Amplia TherapeuticsJun 05 2024 - Small Caps |
8 |
Is The Long Wait For CSL About To End?May 30 2024 - Technicals |
9 |
Dr Boreham’s Crucible: InvionMay 13 2024 - Small Caps |
10 |
Dr Boreham’s Crucible: Race OncologyApr 09 2024 - Small Caps |